China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
One Percent Rule Checklist For Safer Forex Trading Risk 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
CLEVELAND, April 10, 2017 -- Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2017 financial results at approximately 4:00 PM Eastern Time on Tuesday, May 9, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | May 9, 2017 | |
| Time | 4:30 p.m. (Eastern Time) | |
| Telephone access: US and Canada | (800) 273-1254 | |
| Telephone access: International | (973) 638-3440 | |
| Access code | 5869094 | |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 5869094.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected] David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 [email protected] Investor Contact: Peter Vozzo Westwicke Partners (443) 213-0505 or (443) 377-4767 (mobile) [email protected]
